TransArterial ChemoEmbolization (TACE) with platinum versus anthracyclines for hepatocellular carcinoma: A meta-analysis

被引:11
|
作者
Zhao, Mengdie [1 ]
Xiang, Ping [2 ]
Jiang, Hao [1 ]
机构
[1] Bengbu Med Coll, Affiliated Hosp 1, Dept Radiat Oncol, Bengbu 233004, Anhui, Peoples R China
[2] Bengbu Med Coll, Affiliated Hosp 1, Cent Lab, Bengbu 233004, Anhui, Peoples R China
关键词
HCC; TACE; Platinum; Anthracyclines; Meta-analysis; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; DRUG-ELUTING BEADS; CANCER; EPIRUBICIN; MIRIPLATIN; MICROSPHERES;
D O I
10.1016/j.ijsu.2018.03.049
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To determine the clinical efficacy of TACE with platinum versus anthracyclines for hepatocellular carcinoma (HCC) patients using a meta-analysis. Methods: We conducted a systematic review of the literature in PubMed, Embase, and the Cochrane Library database to discover relevant randomized controlled trials (RCTs) and observational studies. Data on therapeutic response, adverse event and overall survival rate from studies that compared TACE with platinum versus anthracyclines for HCC patients was extracted for pooled estimation. Subgroup analysis was used if further investigation was needed. The Q statistic and the I-2 index statistic were used to assess heterogeneity. Publication bias was evaluated using Egger's test. Results: Four RCTs and seven observational studies containing 1405 patients were included in this meta-analysis. After comparing RCTs and observational studies separately, the pooled estimation results indicated that no significant difference existed between platinum and anthracyclines regarding therapeutic response, adverse event and overall survival rate. Furthermore, Egger's test revealed bias in pooled estimation of survival rate among RCTs. Conclusions: Based on current results, we concluded that TACE with platinum revealed similar clinical efficacy compared with anthracyclines. And more relative studies in this field were expected in the future.
引用
收藏
页码:151 / 158
页数:8
相关论文
共 50 条
  • [1] Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis
    Zhang, Leida
    Hu, Peng
    Chen, Xi
    Bie, Ping
    PLOS ONE, 2014, 9 (06):
  • [2] Transarterial radioembolization versus chemoembolization for hepatocellular carcinoma: a meta-analysis
    Lu, Wenxiao
    Zhang, Tongsheng
    Xia, Fengfei
    Huang, Xiangzhong
    Gao, Fulei
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [3] TRANSARTERIAL CHEMOEMBOLIZATION VERSUS TRANSARTERIAL RADIOEMBOLIZATION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA: A META-ANALYSIS
    Brown, Andrew
    Kassab, Ihab A.
    Chen, Vincent L.
    Townsend, Whitney A.
    Singal, Amit G.
    Parikh, Neehar D.
    HEPATOLOGY, 2019, 70 : 234A - 235A
  • [4] Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis
    Duan, Ruihua
    Gong, Fen
    Wang, Yan
    Huang, Caixia
    Wu, Jiaming
    Hu, Leihao
    Liu, Min
    Qiu, Shijun
    Lu, Liming
    Lin, Yisheng
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [5] Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis
    Ruihua Duan
    Fen Gong
    Yan Wang
    Caixia Huang
    Jiaming Wu
    Leihao Hu
    Min Liu
    Shijun Qiu
    Liming Lu
    Yisheng Lin
    World Journal of Surgical Oncology, 21
  • [6] Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis
    Zhang, XiuPing
    Wang, Kang
    Wang, Meng
    Yang, Guang
    Ye, XiaoFei
    Wu, MengChao
    Cheng, ShuQun
    ONCOTARGET, 2017, 8 (17) : 29416 - 29427
  • [7] Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis
    Tian, Xin
    Dai, Ying
    Wang, Da-qing
    Zhang, Li
    Sui, Cheng-guang
    Meng, Fan-dong
    Jiang, Shen-yi
    Liu, Yun-peng
    Jiang, You-hong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4431 - 4440
  • [8] Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis
    Jia-yan Ni
    Shan-shan Liu
    Lin-feng Xu
    Hong-liang Sun
    Yao-ting Chen
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 653 - 659
  • [9] Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis
    Ni, Jia-yan
    Liu, Shan-shan
    Xu, Lin-feng
    Sun, Hong-liang
    Chen, Yao-ting
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (04) : 653 - 659
  • [10] Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis
    Hu, M-D.
    Jia, L-H.
    Liu, H-B.
    Zhang, K-H.
    Guo, G-H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (01) : 64 - 74